Navigation Links
LA BioMed receives Grand Challenges Explorations grant
Date:5/15/2012

LOS ANGELES (May 15, 2012) The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Frans J. Walther, M.D., Ph.D., FAAP, LA BioMed lead investigator and Professor of Pediatrics at UCLA, will pursue an innovative global health and development research project, titled "Aerosol Delivery of Synthetic Lung Surfactant."

Grand Challenges Explorations (GCE) funds individuals worldwide to explore ideas that can break the mold in how we solve persistent global health and development challenges. Dr. Walther's project is one of over 100 Grand Challenges Explorations Round 8 grants announced today by the Bill & Melinda Gates Foundation.

"Grand Challenges Explorations encourages individuals worldwide to expand the pipeline of ideas where creative, unorthodox thinking is most urgently needed," said Chris Wilson, director of Global Health Discovery and Translational Sciences at the Bill & Melinda Gates Foundation. "We're excited to provide additional funding for select grantees so that they can continue to advance their idea towards global impact."

To receive funding, Dr. Walther and other Grand Challenges Explorations Round 8 winners demonstrated in a two-page online application a bold idea in one of five critical global heath and development topic areas that included agriculture development, immunization and nutrition. Applications for the current open round, Grand Challenges Explorations Round 9, will be accepted through May 15, 2012.

Seven percent of all infants are born prematurely. Half of them develop breathing problems because their lungs are immature and lack surfactant, a substance consisting of lipids and proteins that reduces surface tension in the lungs and is pivotal in keeping lungs open during expiration. The application of continuous positive airway pressure (CPAP) via the nose throughout the respiratory cycle during spontaneous breathing has revolutionized the treatment of respiratory failure in premature infants.

Nasal CPAP assists in opening and keeping open the lungs from birth onwards and is applicable in both high and low technical settings. If this noninvasive approach fails, the next step is to insert a breathing tube, start mechanical ventilation, and instill a clinical lung surfactant into the airways. This approach is not only invasive, but may damage the lungs and requires advanced skills and equipment. Delivery of an advanced synthetic lung surfactant as an aerosol will open up the possibility to use this rescue treatment in a non-invasive way. The combination of nasal CPAP and aerosolized synthetic lung surfactant will first be tested in a laboratory setting. If successful , this new approach will be further developed for clinical use.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Biomedical researchers receive Hartwell Foundation awards
2. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
3. LA BioMed investigators uncover new advancements in cardiovascular medicine
4. CCNYs Robert Alfano wins first biomedical optics award
5. LA BioMed investigators lead first survey to determine hospital EDs pediatric readiness
6. Nations largest federation of biological and biomedical organizations welcomes 2 new members
7. Virginia Techs Rylander wins national biomedical engineering award
8. Swedish people are quick to adopt JoVE, a video journal for biomedical sciences
9. Report calls for creation of a biomedical research and patient data network for more accurate classification of diseases, move toward precision medicine
10. LA BioMeds Dr. Ronald Oudiz impacting lives of those with pulmonary hypertension
11. Dartmouth Med School lands $11M grant for regional biomedical research center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology: